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Why were oral corticosteroids not used to treat relapses of MS before 2015?
Until recently, the practice usually recommended was to use high doses of methylprednisolone given intravenously, on the basis of four randomised placebocontrolled studies including a total of 193 MS patients, [1] [2] [3] [4] and of the Optic Neuritis Treatment Trial (ONTT), 5-7 a much larger study including nearly 450 patients presenting with a first episode of optic neuritis. The results of the ONTT showed that the group receiving methylprednisolone 1 g/day intravenously for 3 days followed by oral tapering recovered more rapidly than the group receiving oral low doses of methylprednisolone (1 mg/kg/day for 14 days). Moreover, the oral group more frequently presented with new relapses during the following 10 years compared with the intravenous and placebo groups. 8 Oral corticosteroids were then considered ineffective and even deleterious for the treatment of MS relapses. But important limitations of the ONTT were identified: it included a population of optic neuritis and not of MS patients, low doses of corticosteroids were used orally versus high doses intravenously, and it was not adequately controlled since control groups did not receive any infusion. The question remained debated and the saga of oral versus intravenous corticosteroids continued with five new randomised controlled trials including 215 MS patients. 9-13 Finally, a meta-analysis 14 published in 2012 pooled the data of these five trials and concluded that there was no significant difference between the oral and intravenous administration of corticosteroids for the treatment of MS relapses but that the results remained insufficient to recommend oral treatment because of lack of power and major methodological limitations such as time from onset of relapse to first dose of up to 1 month (period by which time the resolution phase has already spontaneously started 9,10 ), lack of reliable concealment of allocation or randomisation method, failure to use bioequivalent dosing (oral regimen 10 times lower than the intravenous one in the largest study 9 ) and lack of evidence that an appropriate assessment was conducted. Only one study 12 employed proper equivalence design techniques, but the patients and the clinical assessors of Expanded Disability Status Scale (EDSS) and adverse events (AEs) were not blinded. Moreover, none of these trials evaluated precisely if the tolerance was worse orally than intravenously. So doubts about the use of oral corticosteroids persisted ….
2015: The COPOUSEP trial gave a powerful positive response to this eternal question of oral corticosteroids for relapses treatment in MS
Indeed, the COPOUSEP trial 15 was the first level 1b study demonstrating non-inferior efficacy and safety of oral versus intravenous high-dose methylprednisolone for relapse treatment in MS, taking into account the potential benefits of the procedure. The methodology resolved the weaknesses of previous trials since it was a randomised, double-blind, non-inferiority trial, adequately powered (200 patients; non-inferiority margin δ of an absolute 15% difference between treatment groups), comparing a similar dosage of methylprednisolone oral versus intravenous, given early after onset of a relapse (less than 2 weeks). Results confirmed that methylprednisolone 1 g/day for 3 days was not less efficient orally than intravenously in terms of recovery 1 and 6 months after corticosteroids onset and in terms of new relapses for up to 6 months, tolerability being similar except for more frequent insomnia for the oral regimen. This was demonstrated in pure relapsing MS patients presenting with a significant relapse as defined by the Functional System Score (FSS). Because the authors considered that relapses are more accurately described by determining the functional system the mostly affected, they used the same parameter to assess the primary outcome at 1 month, even though in the literature, the EDSS score was generally used. Finally, results were very similar, whether looking at the most affected FSS score or at the overall EDSS score, with 80.5% (66 of 82) of patients achieving the primary outcome and 77% (63 of 82) of patients improving by at least 1.0 EDSS point by Day 28 in the oral group (80% (72 of 90) and 76% (68 of 90) in the intravenous group). Patients were enrolled no more than 15 days after relapse onset, to avoid missing the hypothetical window in which oral and intravenous steroid therapy might differ in efficacy, with quite a short median time to treatment start of 7 days in the oral group and 7.4 days in the intravenous group. These results give some insight into the benefits of early administration of methylprednisolone high dose (oral or intravenous) for treating relapses since the median time to full recovery was of 1.5 month and 64% (128 of 199) of the intention-to-treat population was deemed to fully recover up to 6 months, meaning that 36% (71 of 199) had residual signs confirmed by the treating physician. There are few data in the literature about the kinetics of recovery after a relapse of MS, but when Lublin et al. 16 analysed patients from the placebo arms of two trials, they found that 57% (of the 140 patients having an EDSS increase during relapse) had a residual deficit of at least 0.5 EDSS points for an average of 2 months after the relapse. However, the comparison should be cautious since the context of the study, the parameters analysed and the period of assessment were different. Further study should be conducted to confirm if the rapidity to start corticosteroids is associated with a lower risk of residual deficit after a relapse of MS.
Oral rather than intravenous corticosteroids should be used to treat MS relapses -Yes Emmanuelle Le Page and Gilles Edan

What are the potential advantages of treating relapses of MS orally instead of intravenously and how to deal with the new procedure in real life?
The COPOUSEP results provide strong arguments for the possibility of improving MS relapse management since oral treatment ensures a simpler procedure, which is less invasive and more convenient for patients, supports a more rapid treatment response and savings in costs and logistics. 17 However, it might increase non-specialists' use of oral corticosteroids without consideration of the indication. It is important to remind that even if not more frequently orally than intravenously, high-dose methylprednisolone can be responsible for adverse effects 15 justifying that the indication must be validated by a neurologist after clinical confirmation of a relapse and the need to treat it with high-dose methylprednisolone. Furthermore, relapses remain a tool of assessing disease-modifying drugs response combined with magnetic resonance imaging (MRI) monitoring of MS activity as illustrated over the last 10 years. 18 In daily life, educational programmes for patients and neurologists should be developed to secure this practice.
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Many forms of corticosteroids have been used to treat multiple sclerosis (MS) since the first clinical trial in 1961. 1 Debates about dose, route of administration, and efficacy have been heightened by demands for more convenient and cheaper therapies. A particularly important question is whether oral therapies can be substituted for intravenous corticosteroids.
The study that has most influenced the use of intravenous corticosteroids is the Optic Neuritis Treatment Trial (ONTT), a three-armed study comparing oral placebo (n = 150), methylprednisolone 250 mg intravenously four times a day for 3 days plus prednisone 1 mg/kg/day for 11 days (n = 151), or prednisone 1 mg/kg/day for 14 days (n = 156) in patients with acute optic neuritis. 2 Both corticosteroid groups had modest visual improvement compared to placebo, with methylprednisolone having a greater effect than oral prednisone, though these effects faded by 6 months. More concerning, the oral prednisone group had almost twice as many subsequent attacks of optic neuritis (27%) as the placebo (15%) or methylprednisolone (13%) groups over 24 months, and a greater proportion of people developing MS with prednisone (24%) compared to methylprednisolone (14%) or placebo (20%). Although the methodology and analysis have been criticized, 1 the ONTT suggested that oral corticosteroids alone may increase the long-term risk of subsequent demyelinating events, leading many to exclusively recommend intravenous treatment.
One of the most obvious explanations for the results of the ONTT is that they may reflect a difference in dose rather than route. The relative potency of 1000 mg methylprednisolone is equivalent to 1250 mg prednisone or 200 mg dexamethasone. 1 Some have advocated simply giving the oral equivalent doses of these three corticosteroids since the bioavailability of oral preparations is approximately 80%-90%. 3 For example, one large-scale clinical trial compared 1400 mg of oral and 1000 mg of intravenous methylprednisolone, allowing for an estimated 70% oral bioavailability. 4 This strategy, though likely better than using lower doses, betrays differences in pharmacokinetic parameters such as peak plasma concentrations and elimination half-life. Pharmacodynamic parameters such as the concentration producing half maximal effects also determine the duration and intensity of corticosteroid effects. 3 Determining equivalent doses of prednisone is difficult because of the complicated metabolism to
